Racial/Ethnic Demographics of Participants in Clinical trials of Biologics Used for Asthma

Susamita Kesh
Children's Mercy Hospital Department of Pediatrics, skesh@cmh.edu

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/researchdays

Part of the Higher Education and Teaching Commons, Medical Education Commons, Pediatrics Commons, and the Science and Mathematics Education Commons


This Poster Presentation is brought to you for free and open access by the CONFERENCES, EVENTS, GRAND ROUNDS at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact bpfannenstiel@cmh.edu.
Racial/Ethnic Demographics of Participants in Clinical trials of Biologics Used for Asthma

Submit/Presenting Author (must be a trainee): Susamita Kesh
(Of note, would not be able to do a presentation on May 16th)
Primary Email Address: skesh@cmh.edu

X Resident/Psychology Intern
☐ Fellow

Primary Mentor (one name only): Bridgette Jones, MD MS
Other authors/contributors involved in project:

IRB Number: NA

Describe role of Submitting/Presenting Trainee in this project (limit 150 words):

Presenting Trainee worked on data collection, abstract write up, and poster creation for the project.

Background, Objectives/Goal, Methods/Design, Results, Conclusions limited to 500 words

Background:

African American (AA) and Hispanic patients suffer disproportionately from severe asthma, however are often under-represented within clinical trials of asthma therapies. Monoclonal antibody therapies are shown to be effective in trials to treat patients with severe asthma phenotype.

Objectives/Goal:
We aimed to describe the racial/ethnic makeup of FDA approved biological therapies for asthma.

Methods/Design:

We identified clinical trials in ClinicalTrials.gov of Omalizumab, Mepolizumab, and Reslizumab that assessed safety/efficacy for asthma. The search strategy included the terms “asthma,” drug name, and “United States”. We determined frequency (%) of studies where study participant racial/ethnic demographics were reported; and among these studies the % of racial/ethnic minority inclusion.

Results:
Among the n=29 studies, racial/ethnic demographics were reported in ClinicalTrials.gov for 25% (3 out of 12 studies), 100% (11 out of 11 studies), 83% (5 out of 6 studies) for Omalizumab, Mepolizumab, and Reslizumab respectively. For Omalizumab, mean% (SD) of racial demographics for study participants were: 40.2% (32.8) AA, 41% (40) Caucasian, 6.65% (14.6) Hispanic. Mepolizumab study demographic mean% (SD) were: 5.4 % (5.8) were AA, 83.9 (10.5) were Caucasian, 0% (0) were Hispanic. Among the Reslizumab studies, mean% (SD) of ethnic/racial demographics were: 9.22% (10.1) AA, 74% (4.62) Caucasian, 13.5% (37.9) Hispanic.

Conclusions:

Racial/ethnic demographic data are reported for the majority of clinical trials of biological therapies to treat asthma. However, the racial/ethnic makeup of these trials are often not representative of the US asthma population. Future trials to establish asthma therapeutic efficacy/safety should be conducted amongst a representative population.